VCEL Stock Overview
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.
Vericel Corporation Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$21.09|
|52 Week High||US$43.97|
|52 Week Low||US$17.30|
|1 Month Change||-19.96%|
|3 Month Change||-18.45%|
|1 Year Change||-43.47%|
|3 Year Change||11.35%|
|5 Year Change||334.85%|
|Change since IPO||-98.12%|
Recent News & Updates
Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)Apr 19
Vericel Corporation's (NASDAQ:VCEL) Intrinsic Value Is Potentially 19% Below Its Share PriceAug 09
Statutory Profit Doesn't Reflect How Good Vericel's (NASDAQ:VCEL) Earnings AreMar 03
Is Vericel Corporation's (NASDAQ:VCEL) Recent Stock Performance Influenced By Its Fundamentals In Any Way?Feb 26
|VCEL||US Biotechs||US Market|
Return vs Industry: VCEL underperformed the US Biotechs industry which returned -14.4% over the past year.
Return vs Market: VCEL underperformed the US Market which returned -18.5% over the past year.
|VCEL Average Weekly Movement||12.3%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: VCEL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: VCEL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Vericel Corporation Fundamentals Summary
|VCEL fundamental statistics|
Is VCEL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VCEL income statement (TTM)|
|Cost of Revenue||US$53.69m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.38|
|Net Profit Margin||-11.36%|
How did VCEL perform over the long term?See historical performance and comparison